Liege

• A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in A … Recruiting
  2025-522522-13-01 4 2026-04-08 Duchenne muscular dystrophy
• A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination with Atezolizumab … Recruiting
  2024-517490-24-00 4 2026-03-31 Small Cell Lung Cancer
• A study to test how well PLENVU®, a bowel cleansing medicine, works in children and teenagers before they have a colonoscopy exam Recruiting
  2025-522046-42-00 5 2026-03-24 Colonic disease
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-522713-29-00 5 2026-03-12 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• A Study Testing a New Targeted Drug (TUB-040) in combination with Standard Chemotherapy for Women with Ovarian Cancer Recruiting
  2025-524691-33-00 9 2026-03-09 High-grade epithelial serous or endometrioid epithelial ovarian cancer
• Beamion LUNG-3: A study to test whether zongertinib helps people with surgically removed, non-small cell lung cancer with HER2 mutations com … Recruiting
  2025-521284-12-00 5 2026-03-05 Non-small cell lung cancer
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases
• Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs Recruiting
  2025-523297-16-00 1 2026-02-27 Non-Hodgkin Lymphoid Malignancies (NHLs)
• Radiopharmaceutical treatment of advanced kidney cancer Recruiting
  2024-517899-38-00 4 2026-02-25 Clear Cell Renal Cell Carcinoma (ccRCC)
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting
  2025-522873-12-00 5 2026-02-24 ER+, HER2- Advanced Breast Cancer
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad … Recruiting
  2025-521124-29-00 10 2026-02-13 Non-Small Cell Lung Cancer
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• Phase 2 Study of INCB123667 in Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression Recruiting
  2025-521513-14-00 4 2026-02-10 Ovarian Cancer
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Intravenous Mirvetuximab Soravtansin … Recruiting
  2025-521606-18-00 4 2026-01-29 Ovarian Cancer
• Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af … Recruiting
  2025-522400-24-00 10 2026-01-27 Metastatic urothelial cancer
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• A study to learn more about how well finerenone works, how safe it is, and how it moves into, through, and out of the body compared to place … Recruiting
  2024-519829-38-00 5 2026-01-09 Heart failure due to systemic left ventricular systolic dysfunction
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate
• A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diab … Recruiting
  2024-519494-19-00 5 2025-12-22 Nutritional and metabolic diseases
• A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Fluorouracil, … Recruiting
  2024-513008-32-00 4 2025-12-17 Adenocarcinoma of the gastroesophageal junction
• A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy Recruiting
  2024-520130-29-00 4 2025-12-17 Spinal Muscular Atrophy
• A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic … Recruiting
  2025-522860-34-00 5 2025-12-16 Chronic lymphocytic leukemia (CLL)

Showing 121–144 of 639 trials